Abstract
Two technologies that have emerged in the last decade offer a new paradigm for modern pharmacology, as well as drug discovery and development. Quantitative systems pharmacology (QSP) is a complementary approach to traditional, target-centric pharmacology and drug discovery and is based on an iterative application of computational and systems biology methods with multiscale experimental methods, both of which include models of ADME-Tox and disease. QSP has emerged as a new approach due to the low efficiency of success in developing therapeutics based on the existing target-centric paradigm. Likewise, human microphysiology systems (MPS) are experimental models complementary to existing animal models and are based on the use of human primary cells, adult stem cells, and/or induced pluripotent stem cells (iPSCs) to mimic human tissues and organ functions/structures involved in disease and ADME-Tox. Human MPS experimental models have been developed to address the relatively low concordance of human disease and ADME-Tox with engineered, experimental animal models of disease. The integration of the QSP paradigm with the use of human MPS has the potential to enhance the process of drug discovery and development.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Phys 153:586–600. https://doi.org/10.1152/ajplegacy.1948.153.3.586
Alex A, Harris CJ, Keighley WW, Smith DA (2015) Compound Attrition in Phase II/III. In: Attrition in the pharmaceutical industry. https://doi.org/10.1002/9781118819586.ch4
Al-Hadiya BM, Bakheit AH, Abd-Elgalil AA (2014) Imatinib mesylate. Profiles Drug Subst Excip Relat Methodol 39:265–297. https://doi.org/10.1016/b978-0-12-800173-8.00006-4
Allarakhia M (2013) Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Devel Ther 7:753–766. https://doi.org/10.2147/dddt.S46289
Allen GD (1990) MODFIT: a pharmacokinetics computer program. Biopharm Drug Dispos 11:477–498
Anstee QM, Day CP (2013) The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 10:645–655. https://doi.org/10.1038/nrgastro.2013.182
Arrowsmith J, Miller P (2013) Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov 12:569. https://doi.org/10.1038/nrd4090
Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3:673–683. https://doi.org/10.1038/nrd1468
Ashworth WB, Davies NA, Bogle ID (2016) A computational model of hepatic energy metabolism: understanding zonated damage and steatosis in NAFLD. PLoS Comput Biol 12:e1005105. https://doi.org/10.1371/journal.pcbi.1005105
Atchison L, Zhang H, Cao K, Truskey GA (2017) A tissue engineered blood vessel model of hutchinson-gilford progeria syndrome using human iPSC-derived smooth muscle cells. Sci Rep 7:8168. https://doi.org/10.1038/s41598-017-08632-4
Auner A, Tasneem KM, Markov DA, McCawley LJ, Hutson MS (2019) Chemical-PDMS binding kinetics and implications for bioavailability in microfluidic devices. Lab Chip. https://doi.org/10.1039/C8LC00796A
Bailey T et al (2013) Practical guidelines for the comprehensive analysis of ChIP-seq data. PLoS Comput Biol 9:e1003326. https://doi.org/10.1371/journal.pcbi.1003326
Bakan A, Nevins N, Lakdawala AS, Bahar I (2012) Druggability assessment of allosteric proteins by dynamics simulations in the presence of probe molecules. J Chem Theory Comput 8:2435–2447. https://doi.org/10.1021/ct300117j
Bakan A, Kapralov AA, Bayir H, Hu F, Kagan VE, Bahar I (2015) Inhibition of peroxidase activity of cytochrome c: de novo compound discovery and validation. Mol Pharmacol 88:421–427. https://doi.org/10.1124/mol.115.097816
Barry C et al (2017) Uniform neural tissue models produced on synthetic hydrogels using standard culture techniques. Exp Biol Med 242:1679–1689. https://doi.org/10.1177/1535370217715028
Bartol TM, Bromer C, Kinney J, Chirillo MA, Bourne JN, Harris KM, Sejnowski TJ (2015) Nanoconnectomic upper bound on the variability of synaptic plasticity. elife 4:e10778. https://doi.org/10.7554/eLife.10778
Beckwitt CH, Clark AM, Wheeler S, Taylor DL, Stolz DB, Griffith L, Wells A (2018) Liver ‘organ on a chip’. Exp Cell Res 363:15–25. https://doi.org/10.1016/j.yexcr.2017.12.023
Benam KH et al (2015) Engineered in vitro disease models. Annu Rev Pathol 10:195–262. https://doi.org/10.1146/annurev-pathol-012414-040418
Besser RR, Ishahak M, Mayo V, Carbonero D, Claure I, Agarwal A (2018) Engineered microenvironments for maturation of stem cell derived cardiac myocytes. Theranostics 8:124–140. https://doi.org/10.7150/thno.19441
Bhatia SN, Ingber DE (2014) Microfluidic organs-on-chips. Nat Biotechnol 32:760–772. https://doi.org/10.1038/nbt.2989
Bhushan A et al (2013) Towards a three-dimensional microfluidic liver platform for predicting drug efficacy and toxicity in humans. Stem Cell Res Ther 4(Suppl 1):S16. https://doi.org/10.1186/scrt377
Bian YM, He XB, Jing YK, Wang LR, Wang JM, Xie XQ (2019) Computational systems pharmacology analysis of cannabidiol: a combination of chemogenomics-knowledgebase network analysis and integrated in silico modeling and simulation. Acta Pharmacol Sin 40:374–386. https://doi.org/10.1038/s41401-018-0071-1
Black JR, Clark SJ (2016) Age-related macular degeneration: genome-wide association studies to translation. Genet Med 18:283–289. https://doi.org/10.1038/gim.2015.70
Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM (1972) Definition and antagonism of histamine H2-receptors. Nature 236:385–390
Bleakley K, Yamanishi Y (2009) Supervised prediction of drug-target interactions using bipartite local models. Bioinformatics 25:2397–2403. https://doi.org/10.1093/bioinformatics/btp433
Blutt SE et al (2017) Gastrointestinal microphysiological systems. Exp Biol Med 242:1633–1642. https://doi.org/10.1177/1535370217710638
Bredel M, Jacoby E (2004) Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 5:262–275. https://doi.org/10.1038/nrg1317
Brennan RJ, Nikolskya T, Bureeva S (2009) Network and pathway analysis of compound-protein interactions. Methods Mol Biol (Clifton, NJ) 575:225–247. https://doi.org/10.1007/978-1-60761-274-2_10
Buhule OD et al (2014) Stratified randomization controls better for batch effects in 450K methylation analysis: a cautionary tale. Front Genet 5:354. https://doi.org/10.3389/fgene.2014.00354
Byvatov E, Fechner U, Sadowski J, Schneider G (2003) Comparison of support vector machine and artificial neural network systems for drug/nondrug classification. J Chem Inf Comput Sci 43:1882–1889. https://doi.org/10.1021/ci0341161
Cao DS, Zhang LX, Tan GS, Xiang Z, Zeng WB, Xu QS, Chen AF (2014) Computational prediction of drugtarget interactions using chemical, biological, and network features. Mol Inf 33:669–681. https://doi.org/10.1002/minf.201400009
Chen M, Bisgin H, Tong L, Hong H, Fang H, Borlak J, Tong W (2014) Toward predictive models for drug-induced liver injury in humans: are we there yet? Biomark Med 8:201–213. https://doi.org/10.2217/bmm.13.146
Chen X, Yan CC, Zhang X, Zhang X, Dai F, Yin J, Zhang Y (2016) Drug-target interaction prediction: databases, web servers and computational models. Brief Bioinform 17:696–712. https://doi.org/10.1093/bib/bbv066
Chen R, Liu X, Jin S, Lin J, Liu J (2018) machine learning for drug-target interaction prediction. Molecules 23. https://doi.org/10.3390/molecules23092208
Cirit M, Stokes CL (2018) Maximizing the impact of microphysiological systems with in vitro-in vivo translation. Lab Chip 18:1831–1837. https://doi.org/10.1039/c8lc00039e
Clark AM, Ma B, Taylor DL, Griffith L, Wells A (2016) Liver metastases: microenvironments and ex-vivo models. Exp Biol Med 241:1639–1652. https://doi.org/10.1177/1535370216658144
Clark AM et al (2018) A model of dormant-emergent metastatic breast cancer progression enabling exploration of biomarker signatures. Mol Cell Proteomics 17:619–630. https://doi.org/10.1074/mcp.RA117.000370
Cobanoglu MC, Liu C, Hu F, Oltvai ZN, Bahar I (2013) Predicting drug-target interactions using probabilistic matrix factorization. J Chem Inf Model 53:3399–3409. https://doi.org/10.1021/ci400219z
Cobanoglu MC, Oltvai ZN, Taylor DL, Bahar I (2015) BalestraWeb: efficient online evaluation of drug-target interactions. Bioinformatics (Oxford, England) 31:131–133. https://doi.org/10.1093/bioinformatics/btu599
Conesa A et al (2016) A survey of best practices for RNA-seq data analysis. Genome Biol 17:13. https://doi.org/10.1186/s13059-016-0881-8
Costello JC et al (2014) A community effort to assess and improve drug sensitivity prediction algorithms. Nat Biotechnol 32:1202 EP. https://doi.org/10.1038/nbt.2877. https://www.nature.com/articles/nbt.2877#supplementary-information
De Vivo M, Masetti M, Bottegoni G, Cavalli A (2016) Role of molecular dynamics and related methods in drug discovery. J Med Chem 59:4035–4061. https://doi.org/10.1021/acs.jmedchem.5b01684
Digles D et al (2016) Open PHACTS computational protocols for in silico target validation of cellular phenotypic screens: knowing the knowns. Med Chem Commun 7:1237–1244. https://doi.org/10.1039/c6md00065g
Dudley JT et al (2011) Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 3:96ra76
Dutta D, Heo I, Clevers H (2017) Disease modeling in stem cell-derived 3D organoid systems. Trends Mol Med 23:393–410. https://doi.org/10.1016/j.molmed.2017.02.007
Dutta-Moscato J, Solovyev A, Mi Q, Nishikawa T, Soto-Gutierrez A, Fox IJ, Vodovotz Y (2014) A multiscale agent-based in silico model of liver fibrosis progression. Front Bioeng Biotechnol 2:18. https://doi.org/10.3389/fbioe.2014.00018
Dziuba J et al (2014) Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes. Diabetes Obes Metab 16:628–635. https://doi.org/10.1111/dom.12261
Edington CD et al (2018) Interconnected microphysiological systems for quantitative biology and pharmacology studies. Sci Rep 8:4530. https://doi.org/10.1038/s41598-018-22749-0
Erdem C et al (2016) Proteomic screening and lasso regression reveal differential signaling in insulin and insulin-like growth factor I (IGF1) pathways. Mol Cell Proteomics 15:3045–3057. https://doi.org/10.1074/mcp.M115.057729
Esch EW, Bahinski A, Huh D (2015) Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov 14:248–260. https://doi.org/10.1038/nrd4539
Ewart L et al (2017) Navigating tissue chips from development to dissemination: a pharmaceutical industry perspective. Exp Biol Med 242:1579–1585. https://doi.org/10.1177/1535370217715441
Ewart L et al (2018) Application of microphysiological systems to enhance safety assessment in drug discovery. Annu Rev Pharmacol Toxicol 58:65–82. https://doi.org/10.1146/annurev-pharmtox-010617-052722
Fang Y, Eglen RM (2017) Three-dimensional cell cultures in drug discovery and development. SLAS Discov Adv Life Sci R & D 22:456–472. https://doi.org/10.1177/1087057117696795
Fatehullah A, Tan SH, Barker N (2016) Organoids as an in vitro model of human development and disease. Nat Cell Biol 18:246–254. https://doi.org/10.1038/ncb3312
Ferdinandy P et al (2018) Definition of hidden drug cardiotoxicity: paradigm change in cardiac safety testing and its clinical implications. Eur Heart J. https://doi.org/10.1093/eurheartj/ehy365
Ferreira LLG, Andricopulo AD (2019) ADMET modeling approaches in drug discovery. Drug Discov Today. https://doi.org/10.1016/j.drudis.2019.03.015
Floris M, Olla S, Schlessinger D, Cucca F (2018) Genetic-driven druggable target identification and validation. Trends Genet 34:558–570. https://doi.org/10.1016/j.tig.2018.04.004
Gadkar K, Kirouac D, Parrott N, Ramanujan S (2016a) Quantitative systems pharmacology: a promising approach for translational pharmacology. Drug Discov Today Technol 21–22:57–65. https://doi.org/10.1016/j.ddtec.2016.11.001
Gadkar K, Lu J, Sahasranaman S, Davis J, Mazer NA, Ramanujan S (2016b) Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach. J Lipid Res 57:46–55. https://doi.org/10.1194/jlr.M057943
Gaulton A et al (2017) The ChEMBL database in 2017. Nucleic Acids Res 45:D945–D954. https://doi.org/10.1093/nar/gkw1074
Ge SX, Son EW, Yao R (2018) iDEP: an integrated web application for differential expression and pathway analysis of RNA-Seq data. BMC Bioinf 19:534. https://doi.org/10.1186/s12859-018-2486-6
Gerdes MJ et al (2013) Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A 110:11982–11987. https://doi.org/10.1073/pnas.1300136110
Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V (2014) SwissTargetPrediction: a web server for target prediction of bioactive small molecules. Nucleic Acids Res 42:W32–W38. https://doi.org/10.1093/nar/gku293
Goh WWB, Wong L (2018) Dealing with confounders in omics analysis. Trends Biotechnol 36:488–498. https://doi.org/10.1016/j.tibtech.2018.01.013
Goh WWB, Wang W, Wong L (2017) Why batch effects matter in omics data, and how to avoid them. Trends Biotechnol 35:498–507. https://doi.org/10.1016/j.tibtech.2017.02.012
Gough A, Lezon T, Faeder J, Chennubhotla C, Murphy R, Critchley-Thorne R, Taylor DL (2014) High-content analysis with cellular and tissue systems biology: a bridge between cancer cell biology and tissue-based diagnostics. In: Mendelsohn J, Gray JW, Howley PM, Israel MA, Thompson CB (eds) The molecular basis of cancer, 4th edn. Elsevier, New York, pp 369–392.e367. https://doi.org/10.1016/B978-1-4557-4066-6.00025-1
Gough A, Vernetti L, Bergenthal L, Shun TY, Taylor DL (2016) The microphysiology systems database for analyzing and modeling compound interactions with human and animal organ models. Appl In Vitro Toxicol 2:103–117. https://doi.org/10.1089/aivt.2016.0011
Grimes T, Potter SS, Datta S (2019) Integrating gene regulatory pathways into differential network analysis of gene expression data. Sci Rep 9:5479. https://doi.org/10.1038/s41598-019-41918-3
Haasen D, Schopfer U, Antczak C, Guy C, Fuchs F, Selzer P (2017) How phenotypic screening influenced drug discovery: lessons from five years of practice. Assay Drug Dev Technol 15:239–246. https://doi.org/10.1089/adt.2017.796
Hachey SJ, Hughes CCW (2018) Applications of tumor chip technology. Lab Chip 18:2893–2912. https://doi.org/10.1039/c8lc00330k
Hansen J, Iyengar R (2013) Computation as the mechanistic bridge between precision medicine and systems therapeutics. Clin Pharmacol Ther 93:117–128. https://doi.org/10.1038/clpt.2012.199
Hartung T (2009) Toxicology for the twenty-first century. Nature 460:208–212. https://doi.org/10.1038/460208a
Hasin Y, Seldin M, Lusis A (2017) Multi-omics approaches to disease. Genome Biol 18:83. https://doi.org/10.1186/s13059-017-1215-1
He KY, Ge D, He MM (2017) Big data analytics for genomic medicine. Int J Mol Sci 18. https://doi.org/10.3390/ijms18020412
Hill SM et al (2016) Inferring causal molecular networks: empirical assessment through a community-based effort. Nat Methods 13:310–318. https://doi.org/10.1038/nmeth.3773
Hodos RA, Kidd BA, Shameer K, Readhead BP, Dudley JT (2016) In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med 8:186–210
Hopkins AL (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4:682–690. https://doi.org/10.1038/nchembio.118
Horvath P et al (2016) Screening out irrelevant cell-based models of disease. Nat Rev Drug Discov 15:751–769. https://doi.org/10.1038/nrd.2016.175
Hou T, Qiao X, Xu X (2001) Research and development of 3D molecular structure database of traditional Chinese drugs. Acta Chim Sin 59:1788–1792
Howell BA, Siler SQ, Shoda LK, Yang Y, Woodhead JL, Watkins PB (2014) A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial. CPT Pharmacometrics Syst Pharmacol 3:e98. https://doi.org/10.1038/psp.2013.74
Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE (2010) Reconstituting organ-level lung functions on a chip. Science 328:1662–1668. https://doi.org/10.1126/science.1188302
Huntley RP, Sawford T, Mutowo-Meullenet P, Shypitsyna A, Bonilla C, Martin MJ, O’Donovan C (2015) The GOA database: gene ontology annotation updates for 2015. Nucleic Acids Res 43:D1057–D1063. https://doi.org/10.1093/nar/gku1113
Ivetac A, McCammon JA (2012) A molecular dynamics ensemble-based approach for the mapping of druggable binding sites. Methods Mol Biol (Clifton, NJ) 819:3–12. https://doi.org/10.1007/978-1-61779-465-0_1
Iyengar R, Zhao S, Chung SW, Mager DE, Gallo JM (2012) Merging systems biology with pharmacodynamics. Sci Transl Med 4:126ps127. https://doi.org/10.1126/scitranslmed.3003563
Jain MR et al (2015) Saroglitazar, a novel PPAR alpha/gamma agonist with predominant PPAR alpha activity, shows lipid-lowering and insulin-sensitizing effects in preclinical models. Pharmacol Res Perspect 3:e00136. https://doi.org/10.1002/prp2.136
Jain A et al (2018) Primary human lung alveolus-on-a-chip model of intravascular thrombosis for assessment of therapeutics. Clin Pharmacol Ther 103:332–340. https://doi.org/10.1002/cpt.742
Johnson CH, Ivanisevic J, Siuzdak G (2016) Metabolomics: beyond biomarkers and towards mechanisms. Nat Rev Mol Cell Biol 17:451–459. https://doi.org/10.1038/nrm.2016.25
Kalli M, Stylianopoulos T (2018) Defining the role of solid stress and matrix stiffness in cancer cell proliferation and metastasis. Front Oncol 8:55–55. https://doi.org/10.3389/fonc.2018.00055
Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K (2017) KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45:D353–D361. https://doi.org/10.1093/nar/gkw1092
Karczewski KJ, Snyder MP (2018) Integrative omics for health and disease. Nat Rev Genet 19:299–310. https://doi.org/10.1038/nrg.2018.4
Kaya C et al (2018) Heterogeneities in axonal structure and transporter distribution lower dopamine reuptake efficiency. eNeuro 5. https://doi.org/10.1523/ENEURO.0298-17.2017
Keating SM et al (2018) Opportunities and challenges in implementation of multiparameter single cell analysis platforms for clinical translation. Clin Transl Sci 11:267–276. https://doi.org/10.1111/cts.12536
Keiser MJ et al (2009) Predicting new molecular targets for known drugs. Nature 462:175–181. https://doi.org/10.1038/nature08506
Koch CM, Chiu SF, Akbarpour M, Bharat A, Ridge KM, Bartom ET, Winter DR (2018) A beginner’s guide to analysis of RNA sequencing data. Am J Respir Cell Mol Biol 59:145–157. https://doi.org/10.1165/rcmb.2017-0430TR
Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–715. https://doi.org/10.1038/nrd1470
Kooistra AJ, Kanev GK, van Linden OP, Leurs R, de Esch IJ, de Graaf C (2016) KLIFS: a structural kinase-ligand interaction database. Nucleic Acids Res 44:D365–D371. https://doi.org/10.1093/nar/gkv1082
Kuhn M et al (2010) STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res 38:D552–D556. https://doi.org/10.1093/nar/gkp937
Kurdyukov S, Bullock M (2016) DNA methylation analysis: choosing the right method. Biology 5. https://doi.org/10.3390/biology5010003
LaFramboise T (2009) Single nucleotide polymorphism arrays: a decade of biological, computational and technological advances. Nucleic Acids Res 37:4181–4193. https://doi.org/10.1093/nar/gkp552
Lambert CG, Black LJ (2012) Learning from our GWAS mistakes: from experimental design to scientific method. Biostatistics (Oxford, England) 13:195–203. https://doi.org/10.1093/biostatistics/kxr055
Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Jr (1967) Differentiation of receptor systems activated by sympathomimetic amines. Nature 214:597–598
Larance M, Lamond AI (2015) Multidimensional proteomics for cell biology. Nat Rev Mol Cell Biol 16:269–280. https://doi.org/10.1038/nrm3970
Laurie S et al (2016) From wet-lab to variations: concordance and speed of bioinformatics pipelines for whole genome and whole exome sequencing. Hum Mutat 37:1263–1271. https://doi.org/10.1002/humu.23114
Lave T, Caruso A, Parrott N, Walz A (2016) Translational PK/PD modeling to increase probability of success in drug discovery and early development. Drug Discov Today Technol 21–22:27–34. https://doi.org/10.1016/j.ddtec.2016.11.005
Lee E, Chuang HY, Kim JW, Ideker T, Lee D (2008) Inferring pathway activity toward precise disease classification. PLoS Comput Biol 4:e1000217. https://doi.org/10.1371/journal.pcbi.1000217
Lee-Montiel FT et al (2017) Control of oxygen tension recapitulates zone-specific functions in human liver microphysiology systems. Exp Biol Med 242:1617–1632. https://doi.org/10.1177/1535370217703978
Lenguito G et al (2017) Resealable, optically accessible, PDMS-free fluidic platform for ex vivo interrogation of pancreatic islets. Lab Chip 17:772–781. https://doi.org/10.1039/c6lc01504b
Lexa KW, Carlson HA (2011) Full protein flexibility is essential for proper hot-spot mapping. J Am Chem Soc 133:200–202. https://doi.org/10.1021/ja1079332
Lezon TR, Banavar JR, Cieplak M, Maritan A, Fedoroff NV (2006) Using the principle of entropy maximization to infer genetic interaction networks from gene expression patterns. Proc Natl Acad Sci U S A 103:19033–19038. https://doi.org/10.1073/pnas.0609152103
Li Q, Bender A, Pei J, Lai L (2007) A large descriptor set and a probabilistic kernel-based classifier significantly improve druglikeness classification. J Chem Inf Model 47:1776–1786. https://doi.org/10.1021/ci700107y
Li X, George SM, Vernetti L, Gough AH, Taylor DL (2018) A glass-based, continuously zonated and vascularized human liver acinus microphysiological system (vLAMPS) designed for experimental modeling of diseases and ADME/TOX. Lab Chip 18:2614–2631. https://doi.org/10.1039/c8lc00418h
Lin Z, Jaberi-Douraki M, He C, Jin S, Yang RSH, Fisher JW, Riviere JE (2017) Performance assessment and translation of physiologically based pharmacokinetic models from acslX to Berkeley Madonna, MATLAB, and R Language: oxytetracycline and gold nanoparticles as case examples. Toxicol Sci 158:23–35. https://doi.org/10.1093/toxsci/kfx070
Lind JU et al (2017) Cardiac microphysiological devices with flexible thin-film sensors for higher-throughput drug screening. Lab Chip 17:3692–3703. https://doi.org/10.1039/c7lc00740j
Liu Y, Wu M, Miao C, Zhao P, Li XL (2016) Neighborhood regularized logistic matrix factorization for drug-target interaction prediction. PLoS Comput Biol 12:e1004760. https://doi.org/10.1371/journal.pcbi.1004760
Loving KA, Lin A, Cheng AC (2014) Structure-based druggability assessment of the mammalian structural proteome with inclusion of light protein flexibility. PLoS Comput Biol 10:e1003741. https://doi.org/10.1371/journal.pcbi.1003741
Low LA, Tagle DA (2017) Tissue chips – innovative tools for drug development and disease modeling. Lab Chip 17:3026–3036. https://doi.org/10.1039/c7lc00462a
Macintyre G, Van Loo P, Corcoran NM, Wedge DC, Markowetz F, Hovens CM (2017) How subclonal modeling is changing the metastatic paradigm. Clin Cancer Res 23:630–635. https://doi.org/10.1158/1078-0432.CCR-16-0234
Manatakis DV, Raghu VK, Benos PV (2018) piMGM: incorporating multi-source priors in mixed graphical models for learning disease networks. Bioinformatics 34:i848–i856. https://doi.org/10.1093/bioinformatics/bty591
Marnett LJ (2009) The COXIB experience: a look in the rearview mirror. Annu Rev Pharmacol Toxicol 49:265–290. https://doi.org/10.1146/annurev.pharmtox.011008.145638
Martz CA et al (2014) Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal 7:ra121. https://doi.org/10.1126/scisignal.aaa1877
Mateus A, Maatta TA, Savitski MM (2016) Thermal proteome profiling: unbiased assessment of protein state through heat-induced stability changes. Proteome Sci 15:13. https://doi.org/10.1186/s12953-017-0122-4
May S, Evans S, Parry L (2017) Organoids, organs-on-chips and other systems, and microbiota. Emerg Top Life Sci 1:385–400. https://doi.org/10.1042/ETLS20170047
McCauley HA, Wells JM (2017) Pluripotent stem cell-derived organoids: using principles of developmental biology to grow human tissues in a dish. Development 144:958–962. https://doi.org/10.1242/dev.140731
Miedel MT, Gavlock DC, Jia S, Gough A, Taylor DL, Stern AM (2019) Modeling the effect of the metastatic microenvironment on phenotypes conferred by estrogen receptor mutations using a human liver microphysiology system. Sci Rep (final review)
Muller KR, Ratsch G, Sonnenburg S, Mika S, Grimm M, Heinrich N (2005) Classifying ‘drug-likeness’ with kernel-based learning methods. J Chem Inf Model 45:249–253. https://doi.org/10.1021/ci049737o
Musa A et al (2017) A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinform 18:903. https://doi.org/10.1093/bib/bbx023
Mustata G et al (2009) Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J Med Chem 52:1247–1250. https://doi.org/10.1021/jm801278g
Newman RH, Zhang J (2014) The design and application of genetically encodable biosensors based on fluorescent proteins. Methods Mol Biol (Clifton, NJ) 1071:1–16. https://doi.org/10.1007/978-1-62703-622-1_1
Nickel J et al (2014) SuperPred: update on drug classification and target prediction. Nucleic Acids Res 42:W26–W31. https://doi.org/10.1093/nar/gku477
Oleaga C et al (2019) Long-term electrical and mechanical function monitoring of a human-on-a-chip system. Adv Funct Mater 29:1805792. https://doi.org/10.1002/adfm.201805792
Pacana T, Sanyal AJ (2015) Recent advances in understanding/management of non-alcoholic steatohepatitis. F1000Prime Rep 7:28. https://doi.org/10.12703/P7-28
Paul DS et al (2016) Increased DNA methylation variability in type 1 diabetes across three immune effector cell types. Nat Commun 7:13555. https://doi.org/10.1038/ncomms13555. https://www.nature.com/articles/ncomms13555#supplementary-information
Pei F et al (2017) Connecting neuronal cell protective pathways and drug combinations in a huntington’s disease model through the application of quantitative systems pharmacology. Sci Rep 7:17803. https://doi.org/10.1038/s41598-017-17378-y
Pei F, Li H, Liu B, Bahar I (2019) Quantitative systems pharmacological analysis of drugs of abuse reveals the pleiotropy of their targets and the effector role of mTORC1. Front Pharmacol 10:191. https://doi.org/10.3389/fphar.2019.00191
Pollard TD (2010) A guide to simple and informative binding assays. Mol Biol Cell 21:4061–4067. https://doi.org/10.1091/mbc.E10-08-0683
Prathipati P, Mizuguchi K (2016) Systems biology approaches to a rational drug discovery paradigm. Curr Top Med Chem 16:1009–1025
Prestigiacomo V, Weston A, Messner S, Lampart F, Suter-Dick L (2017) Pro-fibrotic compounds induce stellate cell activation, ECM-remodelling and Nrf2 activation in a human 3D-multicellular model of liver fibrosis. PLoS One 12:e0179995. https://doi.org/10.1371/journal.pone.0179995
Pushpakom S et al (2018) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. https://doi.org/10.1038/nrd.2018.168
Rao SS, Kondapaneni RV, Narkhede AA (2019) Bioengineered models to study tumor dormancy. J Biol Eng 13:3. https://doi.org/10.1186/s13036-018-0137-0
Ribas J, Pawlikowska J, Rouwkema J (2018) Microphysiological systems: analysis of the current status, challenges and commercial future. Microphysiol Syst 2
Rowland M, Peck C, Tucker G (2011) Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 51:45–73. https://doi.org/10.1146/annurev-pharmtox-010510-100540
Sadowski J, Kubinyi H (1998) A scoring scheme for discriminating between drugs and nondrugs. J Med Chem 41:3325–3329. https://doi.org/10.1021/jm9706776
Sakolish C et al (2018) Technology transfer of the microphysiological systems: a case study of the human proximal tubule tissue chip. Sci Rep 8:14882. https://doi.org/10.1038/s41598-018-33099-2
Sanders MP, Barbosa AJ, Zarzycka B, Nicolaes GA, Klomp JP, de Vlieg J, Del Rio A (2012) Comparative analysis of pharmacophore screening tools. J Chem Inf Model 52:1607–1620. https://doi.org/10.1021/ci2005274
Satapathy SK, Sanyal AJ (2015) Epidemiology and natural history of nonalcoholic fatty liver disease. Semin Liver Dis 35:221–235. https://doi.org/10.1055/s-0035-1562943
Satoh T et al (2017) A multi-throughput multi-organ-on-a-chip system on a plate formatted pneumatic pressure-driven medium circulation platform. Lab Chip 18:115–125. https://doi.org/10.1039/c7lc00952f
Schenone M, Dancik V, Wagner BK, Clemons PA (2013) Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 9:232–240. https://doi.org/10.1038/nchembio.1199
Schoeberl B et al (2009) Therapeutically targeting ErbB3: a key node in ligand-induced activation of the ErbB receptor-PI3K axis. Sci Signal 2:ra31. https://doi.org/10.1126/scisignal.2000352
Schulze K et al (2015) Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 47:505–511. https://doi.org/10.1038/ng.3252
Schwartz MP et al (2015) Human pluripotent stem cell-derived neural constructs for predicting neural toxicity. Proc Natl Acad Sci U S A 112:12516–12521. https://doi.org/10.1073/pnas.1516645112
Sebastiani P et al (2010) Genetic signatures of exceptional longevity in humans. Science 2010. https://doi.org/10.1126/science.1190532
Sebastiani P et al (2011) Retraction. Science 333:404. https://doi.org/10.1126/science.333.6041.404-a
Sekar JAP, Tapia J-J, Faeder JR (2017) Automated visualization of rule-based models. PLoS Comput Biol 13:e1005857. https://doi.org/10.1371/journal.pcbi.1005857
Senutovitch N, Vernetti L, Boltz R, DeBiasio R, Gough A, Taylor DL (2015) Fluorescent protein biosensors applied to microphysiological systems. Exp Biol Med 240:795–808. https://doi.org/10.1177/1535370215584934
Seok J et al (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 110:3507–3512. https://doi.org/10.1073/pnas.1222878110
Shamir ER, Ewald AJ (2014) Three-dimensional organotypic culture: experimental models of mammalian biology and disease. Nat Rev Mol Cell Biol 15:647–664. https://doi.org/10.1038/nrm3873
Sharma M, Mitnala S, Vishnubhotla RK, Mukherjee R, Reddy DN, Rao PN (2015) The riddle of nonalcoholic fatty liver disease: progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis. J Clin Exp Hepatol 5:147–158. https://doi.org/10.1016/j.jceh.2015.02.002
Shuler ML (2017) Organ-, body- and disease-on-a-chip systems. Lab Chip 17:2345–2346. https://doi.org/10.1039/c7lc90068f
Simian M, Bissell MJ (2017) Organoids: a historical perspective of thinking in three dimensions. J Cell Biol 216:31–40. https://doi.org/10.1083/jcb.201610056
Sin A, Chin KC, Jamil MF, Kostov Y, Rao G, Shuler ML (2004) The design and fabrication of three-chamber microscale cell culture analog devices with integrated dissolved oxygen sensors. Biotechnol Prog 20:338–345. https://doi.org/10.1021/bp034077d
Skardal A, Shupe T, Atala A (2016) Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling. Drug Discov Today 21:1399–1411. https://doi.org/10.1016/j.drudis.2016.07.003
Slenter DN et al (2018) WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research. Nucleic Acids Res 46:D661–D667. https://doi.org/10.1093/nar/gkx1064
Sliz E et al (2018) NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects. Hum Mol Genet 27:2214–2223. https://doi.org/10.1093/hmg/ddy124
Smagris E et al (2015) Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop hepatic steatosis. Hepatology 61:108–118. https://doi.org/10.1002/hep.27242
Smietana K, Siatkowski M, Moller M (2016) Trends in clinical success rates. Nat Rev Drug Discov 15:379–380. https://doi.org/10.1038/nrd.2016.85
Sorger P et al (2011) Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. An NIH White Paper by the QSP Workshop Group – October, 2011
Soto-Gutierrez A, Gough A, Vernetti LA, Taylor DL, Monga SP (2017) Pre-clinical and clinical investigations of metabolic zonation in liver diseases: the potential of microphysiology systems. Exp Biol Med 242:1605–1616. https://doi.org/10.1177/1535370217707731
Spagnolo DM et al (2016) Pointwise mutual information quantifies intratumor heterogeneity in tissue sections labeled with multiple fluorescent biomarkers. J Pathol Inf 7:47. https://doi.org/10.4103/2153-3539.194839
Spagnolo DM et al (2017) Platform for quantitative evaluation of spatial intratumoral heterogeneity in multiplexed fluorescence images. Cancer Res 77:e71–e74. https://doi.org/10.1158/0008-5472.CAN-17-0676
Speliotes EK et al (2011) Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet 7:e1001324. https://doi.org/10.1371/journal.pgen.1001324
Stern AM, Schurdak ME, Bahar I, Berg JM, Taylor DL (2016) A perspective on implementing a quantitative systems pharmacology platform for drug discovery and the advancement of personalized medicine. J Biomol Screen 21:521–534. https://doi.org/10.1177/1087057116635818
Subramanian A et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545–15550. https://doi.org/10.1073/pnas.0506580102
Sun M et al (2018) Effects of matrix stiffness on the morphology, adhesion, proliferation and osteogenic differentiation of mesenchymal stem cells. Int J Med Sci 15:257–268. https://doi.org/10.7150/ijms.21620
Sutherland RM, Inch WR, McCredie JA, Kruuv J (1970) A multi-component radiation survival curve using an in vitro tumour model. Int J Radiat Biol Relat Stud Phys Chem Med 18:491–495
Sweeney LM, Shuler ML, Babish JG, Ghanem A (1995) A cell culture analogue of rodent physiology: application to naphthalene toxicology. Toxicol In Vitro 9:307–316
Szabo A, Merks RM (2013) Cellular potts modeling of tumor growth, tumor invasion, and tumor evolution. Front Oncol 3:87. https://doi.org/10.3389/fonc.2013.00087
Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M (2016) STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res 44:D380–D384. https://doi.org/10.1093/nar/gkv1277
Takebe T, Zhang B, Radisic M (2017) Synergistic engineering: organoids meet organs-on-a-chip. Cell Stem Cell 21:297–300. https://doi.org/10.1016/j.stem.2017.08.016
Tan YM, Worley RR, Leonard JA, Fisher JW (2018) Challenges associated with applying physiologically based pharmacokinetic modeling for public health decision-making. Toxicol Sci 162:341–348. https://doi.org/10.1093/toxsci/kfy010
Taylor DL (2012) A new vision of drug discovery and development. Eur Pharm Rev 17:20–24
Teschendorff AE (2018) Avoiding common pitfalls in machine learning omic data science. Nat Mater. https://doi.org/10.1038/s41563-018-0241-z
Torras N, Garcia-Diaz M, Fernandez-Majada V, Martinez E (2018) Mimicking epithelial tissues in three-dimensional cell culture models. Front Bioeng Biotechnol 6:197. https://doi.org/10.3389/fbioe.2018.00197
Trapnell C et al (2014) The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat Biotechnol 32:381–386. https://doi.org/10.1038/nbt.2859
Trietsch SJ, Israels GD, Joore J, Hankemeier T, Vulto P (2013) Microfluidic titer plate for stratified 3D cell culture. Lab Chip 13:3548–3554. https://doi.org/10.1039/c3lc50210d
Truskey GA et al (2013) Design considerations for an integrated microphysiological muscle tissue for drug and tissue toxicity testing. Stem Cell Res Ther 4(Suppl 1):S10. https://doi.org/10.1186/scrt371
Tsamandouras N, Kostrzewski T, Stokes CL, Griffith LG, Hughes DJ, Cirit M (2017) Quantitative assessment of population variability in hepatic drug metabolism using a perfused three-dimensional human liver microphysiological system. J Pharmacol Exp Ther 360:95–105. https://doi.org/10.1124/jpet.116.237495
Uttam S, Chennubhotla C, Stern AM, Taylor DL (2019) Computational and systems pathology analytics platform applied to hyperplexed fluorescence-labeled patient tissues predicts risk of colorectal cancer recurrence and infers relevant signaling networks. Nat Biotech. in review
Vaidya TR, Ande A, Ait-Oudhia S (2019) Combining multiscale experimental and computational systems pharmacological approaches to overcome resistance to HER2-targeted therapy in breast cancer. J Pharmacol Exp Ther. https://doi.org/10.1124/jpet.118.255752
van den Berg A, Mummery CL, Passier R, van der Meer AD (2019) Personalised organs-on-chips: functional testing for precision medicine. Lab Chip 19:198–205. https://doi.org/10.1039/c8lc00827b
van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O’Collins V, Macleod MR (2010) Can animal models of disease reliably inform human studies? PLoS Med 7:e1000245. https://doi.org/10.1371/journal.pmed.1000245
van Laarhoven T, Nabuurs SB, Marchiori E (2011) Gaussian interaction profile kernels for predicting drug-target interaction. Bioinformatics 27:3036–3043. https://doi.org/10.1093/bioinformatics/btr500
Vernetti LA, Senutovitch N, Boltz R, DeBiasio R, Shun TY, Gough A, Taylor DL (2016) A human liver microphysiology platform for investigating physiology, drug safety, and disease models. Exp Biol Med 241:101–114. https://doi.org/10.1177/1535370215592121
Vernetti L et al (2017) Functional coupling of human microphysiology systems: intestine, liver, kidney proximal tubule, blood-brain barrier and skeletal muscle. Sci Rep 7:42296. https://doi.org/10.1038/srep42296
Visscher PM, Brown MA, McCarthy MI, Yang J (2012a) Five years of GWAS discovery. Am J Hum Genet 90:7–24. https://doi.org/10.1016/j.ajhg.2011.11.029
Visscher PM, Goddard ME, Derks EM, Wray NR (2012b) Evidence-based psychiatric genetics, AKA the false dichotomy between common and rare variant hypotheses. Mol Psychiatry 17:474–485. https://doi.org/10.1038/mp.2011.65
Visser SA, de Alwis DP, Kerbusch T, Stone JA, Allerheiligen SR (2014) Implementation of quantitative and systems pharmacology in large pharma. CPT Pharmacometrics Syst Pharmacol 3:e142. https://doi.org/10.1038/psp.2014.40
Volkamer A, Kuhn D, Rippmann F, Rarey M (2012) DoGSiteScorer: a web server for automatic binding site prediction, analysis and druggability assessment. Bioinformatics 28:2074–2075. https://doi.org/10.1093/bioinformatics/bts310
Wagener M, van Geerestein VJ (2000) Potential drugs and nondrugs: prediction and identification of important structural features. J Chem Inf Comput Sci 40:280–292
Walters WP, Murcko MA (2002) Prediction of ‘drug-likeness’. Adv Drug Deliv Rev 54:255–271
Wang T, Wu MB, Lin JP, Yang LR (2015) Quantitative structure-activity relationship: promising advances in drug discovery platforms. Expert Opin Drug Discovery 10:1283–1300. https://doi.org/10.1517/17460441.2015.1083006
Watson DE, Hunziker R, Wikswo JP (2017) Fitting tissue chips and microphysiological systems into the grand scheme of medicine, biology, pharmacology, and toxicology. Exp Biol Med 242:1559–1572. https://doi.org/10.1177/1535370217732765
Weedon MN et al (2006) A common haplotype of the glucokinase gene alters fasting glucose and birth weight: association in six studies and population-genetics analyses. Am J Hum Genet 79:991–1001. https://doi.org/10.1086/509517
Wei Y et al (2018) GCDB: a glaucomatous chemogenomics database for in silico drug discovery. Database (Oxford) 2018. epublish. https://doi.org/10.1093/database/bay117
Wen M, Zhang Z, Niu S, Sha H, Yang R, Yun Y, Lu H (2017) Deep-learning-based drug-target interaction prediction. J Proteome Res 16:1401–1409. https://doi.org/10.1021/acs.jproteome.6b00618
Wevers NR et al (2016) High-throughput compound evaluation on 3D networks of neurons and glia in a microfluidic platform. Sci Rep 6:38856. https://doi.org/10.1038/srep38856
Wikswo JP et al (2013a) Engineering challenges for instrumenting and controlling integrated organ-on-chip systems. IEEE Trans Biomed Eng 60:682–690. https://doi.org/10.1109/TBME.2013.2244891
Wikswo JP, Curtis EL, Eagleton ZE, Evans BC, Kole A, Hofmeister LH, Matloff WJ (2013b) Scaling and systems biology for integrating multiple organs-on-a-chip. Lab Chip 13:3496–3511. https://doi.org/10.1039/c3lc50243k
Wishart DS (2016) Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov 15:473–484. https://doi.org/10.1038/nrd.2016.32
Wishart DS et al (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46:D1074–D1082. https://doi.org/10.1093/nar/gkx1037
Wood AR et al (2014) Defining the role of common variation in the genomic and biological architecture of adult human height. Nat Genet 46:1173–1186. https://doi.org/10.1038/ng.3097
Woodhead JL, Watkins PB, Howell BA, Siler SQ, Shoda LKM (2017) The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. Drug Metab Pharmacokinet 32:40–45. https://doi.org/10.1016/j.dmpk.2016.11.008
Workman MJ et al (2017) Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system. Nat Med 23:49–59. https://doi.org/10.1038/nm.4233
Wray NR, Wijmenga C, Sullivan PF, Yang J, Visscher PM (2018) Common disease is more complex than implied by the core gene omnigenic model. Cell 173:1573–1580. https://doi.org/10.1016/j.cell.2018.05.051
Wu Y, Wang G (2018) Machine learning based toxicity prediction: from chemical structural description to transcriptome analysis. Int J Mol Sci 19. https://doi.org/10.3390/ijms19082358
Wu M et al (2018) Conditional gene knockout and reconstitution in human iPSCs with an inducible Cas9 system. Stem Cell Res 29:6–14. https://doi.org/10.1016/j.scr.2018.03.003
Wu N, Feng Z, He X, Kwon W, Wang J, Xie XQ (2019) Insight of captagon abuse by chemogenomics knowledgebase-guided systems pharmacology target mapping analyses. Sci Rep 9:2268. https://doi.org/10.1038/s41598-018-35449-6
Xia Z, Wu LY, Zhou X, Wong ST (2010) Semi-supervised drug-protein interaction prediction from heterogeneous biological spaces. BMC Syst Biol 4(Suppl 2):S6. https://doi.org/10.1186/1752-0509-4-s2-s6
Xie N, Tang B (2016) The application of human iPSCs in neurological diseases: from bench to bedside. Stem Cells Int 2016:6484713. https://doi.org/10.1155/2016/6484713
Xu X, Ma S, Feng Z, Hu G, Wang L, Xie XQ (2016) Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study. J Mol Graph Model 70:284–295. https://doi.org/10.1016/j.jmgm.2016.08.001
Yamanishi Y, Araki M, Gutteridge A, Honda W, Kanehisa M (2008) Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 24:i232–i240. https://doi.org/10.1093/bioinformatics/btn162
Yamanishi Y, Kotera M, Moriya Y, Sawada R, Kanehisa M, Goto S (2014) DINIES: drug-target interaction network inference engine based on supervised analysis. Nucleic Acids Res 42:W39–W45. https://doi.org/10.1093/nar/gku337
Yang K, Han X (2016) Lipidomics: techniques, applications, and outcomes related to biomedical sciences. Trends Biochem Sci 41:954–969. https://doi.org/10.1016/j.tibs.2016.08.010
Yin A, Yamada A, Stam WB, van Hasselt JGC, van der Graaf PH (2018) Quantitative systems pharmacology analysis of drug combination and scaling to humans: the interaction between noradrenaline and vasopressin in vasoconstriction. Br J Pharmacol 175:3394–3406. https://doi.org/10.1111/bph.14385
Yu J et al (2015) Quantitative systems pharmacology approaches applied to microphysiological systems (MPS): data interpretation and multi-MPS integration. CPT Pharmacometrics Syst Pharmacol 4:585–594. https://doi.org/10.1002/psp4.12010
Zernov VV, Balakin KV, Ivaschenko AA, Savchuk NP, Pletnev IV (2003) Drug discovery using support vector machines. The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions. J Chem Inf Comput Sci 43:2048–2056. https://doi.org/10.1021/ci0340916
Zhang B, Radisic M (2017) Organ-on-a-chip devices advance to market. Lab Chip 17:2395–2420. https://doi.org/10.1039/c6lc01554a
Zhao S, Iyengar R (2012) Systems pharmacology: network analysis to identify multiscale mechanisms of drug action. Annu Rev Pharmacol Toxicol 52:505–521. https://doi.org/10.1146/annurev-pharmtox-010611-134520
Zhuang X, Lu C (2016) PBPK modeling and simulation in drug research and development. Acta Pharm Sin B 6:430–440. https://doi.org/10.1016/j.apsb.2016.04.004
Zong N, Kim H, Ngo V, Harismendy O (2017) Deep mining heterogeneous networks of biomedical linked data to predict novel drug-target associations. Bioinformatics 33:2337–2344. https://doi.org/10.1093/bioinformatics/btx160
Acknowledgments
Support from the National Institutes of Health awards UG3DK119973 (DLT), R01DK0017781 (DLT), 1UO1 TR002383 (DLT), U24TR002632 (AG/MS), SBIR HHSN271201800008C UO1CA204826 (CC), DA035778 (IB), and P41 GM103712 (IB) is gratefully acknowledged. We also thank the members of the University of Pittsburgh Drug Discovery Institute, the Department of Computational and Systems Biology, and other collaborators at the University of Pittsburgh and beyond for critical discussions.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Taylor, D.L. et al. (2019). Harnessing Human Microphysiology Systems as Key Experimental Models for Quantitative Systems Pharmacology. In: Barrett, J., Page, C., Michel, M. (eds) Concepts and Principles of Pharmacology. Handbook of Experimental Pharmacology, vol 260. Springer, Cham. https://doi.org/10.1007/164_2019_239
Download citation
DOI: https://doi.org/10.1007/164_2019_239
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-35361-2
Online ISBN: 978-3-030-35362-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)